Intrathecal injection ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	3

2. Amyotrophic lateral sclerosis

---

Clinical trials : 624 /  Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05003921 (ClinicalTrials.gov)	February 2022	6/8/2021	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Biological: AlloRx	The Foundation for Orthopaedics and Regenerative Medicine	NULL	Recruiting	N/A	N/A	All	20	Phase 1	Antigua and Barbuda
2	NCT04821479 (ClinicalTrials.gov)	January 1, 2016	19/10/2020	Repeated Mesenchymal Stem Cell Injections in ALS	Safety and Clinical Effects of Repeated Intrathecal Injections of Autologous Mesenchymal Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Biological: Mesenchymal stem cells (MSC)	Hadassah Medical Organization	NULL	Completed	18 Years	65 Years	All	20	Phase 1/Phase 2	NULL
3	NCT01771640 (ClinicalTrials.gov)	August 2013	16/1/2013	Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS	Intrathecal Transplantation of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS	Amyotrophic Lateral Sclerosis	Biological: intrathecal injection	Royan Institute	NULL	Completed	18 Years	65 Years	All	8	Phase 1	Iran, Islamic Republic of